TopiVert debuts with $12.5 million

Newco TopiVert Ltd. (London, U.K.) raised L8 million ($12.5 million) from Imperial Innovations and SV Life Sciences to develop topical medicines for inflammatory diseases of the eye and gut. TopiVert partnered with RespiVert Ltd. to discover and develop narrow-spectrum kinase inhibitors using RespiVert's IP. TopiVert will receive exclusive rights to select and develop compounds for ophthalmic and gastrointestinal inflammatory diseases, while RespiVert will have exclusive rights for other indications. Imperial Innovations' Maina Bhaman joined TopiVert's board. ...